



Food and Drug Administration
OFFICE OF CRIMINAL INVESTIGATIONS
REPORT OF INVESTIGATION

REPORTING OFFICE: San Francisco Resident Office
DOCUMENT NUMBER: 199443
CASE NUMBER: 2010-SFC-735-0280
RELATED CASE NUMBER: (b) (7)(E)
TYPE OF CASE: 735.100, DIETARY SUPPLEMENTS - CDER
CASE TITLE: PRIMORDIAL PERFORMANCE
CASE AGENT: (b) (7)(F)
INVESTIGATION MADE AT: Oakland, CA
INVESTIGATION MADE BY: SA (b) (7)(F)
REPORTING PERIOD: FROM: 08/20/2011 TO: 11/18/2011
STATUS OF CASE: Continued

SYNOPSIS: Case accepted for prosecution; correspondence with CFSAN and FCC.

RESTRICTED INFORMATION

This report is furnished on an official need-to-know basis and must be protected from dissemination which might compromise the best interests of the Food and Drug Administration, Office of Criminal Investigations. This report shall not be released in response to a Freedom of Information Act or Privacy Act request or disseminated to other parties without prior consultation with the FDA Office of Criminal Investigations.

UNAUTHORIZED RELEASE MAY RESULT IN CRIMINAL PROSECUTION

REPORT SUBMITTED BY: (b) (7)(F), Special Agent, DATE: 11/18/2011

REPORT APPROVED BY: Thomas W. Emerick, Special Agent in Charge, DATE: 11/23/2011

DISTRIBUTION: ORIG: SFC
CC: LAC

1. INTRODUCTION:

This case originated after the February 8, 2010, receipt of information from the United States Anti-Doping Agency (USADA) about an email solicitation from PRIMORDIAL PERFORMANCE on the sale of a new product called Superdrone. The email indicates that PRIMORDIAL PERFORMANCE's Superdrone is a "Superdrol-clone" and contains the designer anabolic steroid methylrostanolone. Superdrol (aka methylrostanolone, aka methasteron) is a designer anabolic steroid ^{(b) (7)(E)}

(b) (7)(E)

Reference is made to the Report of Investigation for the period May 24, 2011 through August 19, 2011.

2. DETAILS OF INVESTIGATION:

(b) (7)(F), (b) (5)

On August 30, 2011 SAs ^{(b) (7)(F)} and ^{(b) (7)(F)} met with Assistant United States Attorneys Jeff Nedrow and Matt Parrella who agreed to open a case against Primordial Performance and Eric Potratz.

On September 15, 2011 SA ^{(b) (7)(F)} spoke to Robert Moore, Special Assistant, Division of Dietary Supplement Programs, CFSAN. Moore stated CFSAN received a notification on May 21, 2009 with supporting documentation that androsterone was a metabolite of DHEA and therefore qualified as a dietary ingredient. Androsterone enanthate, found in the Primordial Performance product Ando Hard, also qualifies as a dietary ingredient because the active moiety of the compound is androsterone. ^{(b) (5)}

On October 21, 2011 SA ^{(b) (7)(F)} received an email from Mesmer, which stated, "Mary Jones (Chemist, FCC) and I had a discussion about this yesterday. CFSAN stated that androsterone enanthate is an ester of androsterone and androsterone is a metabolite of DHEA ^{(b) (5)}

^{(b) (5)}. We are willing to discuss this with you, Bob and CFSAN by in a teleconference if needed."

3. JUDICIAL ACTION:

None this reporting period

4. DISPOSITION OF EVIDENCE, CONTRABAND, AND PERSONAL PROPERTY:

None this reporting period.

5. STATUS OF INVESTIGATION:

Continued

6. SUSPECTS/DEFENDANTS/OTHER:

PRIMORDIAL PERFORMANCE

ERIC POTRATZ

^{(b) (6), (b) (7)(C)}

WWW.PRIMORDIALPERFORMANCE.COM

7. ATTACHMENTS:

None